Chronic myelogenous leukemia (CML) results from the neoplastic transformation of primitive
hematopoietic stem cells, and has been classified as a myeloproliferative disorder. The …

The use of tyrosine kinase inhibitors (TKIs) to treat chronic myeloid leukemia (CML)
represents the paradigm for modern targeted cancer therapy. Importantly, molecular …

Mutation in the ABL kinase domain is the principal mechanism of imatinib resistance in
patients with chronic myelogenous leukemia. Many mutations favor active kinase …

PURPOSE: Patients with pediatric acute lymphoblastic leukemia (ALL) are at risk for
impaired physical function from treatment. Early physical therapy (PT) may improve physical …

BACKGROUND. The success of imatinib therapy for chronic myeloid leukemia (CML) has
brought new challenges; these include optimizing disease monitoring, imatinib resistance …

Allogeneic SCT is important in myelodysplastic syndrome, the BCR-ABL-negative chronic
myeloproliferative diseases (CMPDs) and in poor-risk AML. Techniques to monitor the …

Simple Summary Chronic Myelogenous Leukemia (CML) is a common blood cancer that
involves the uncontrolled growth of certain blood cells. Treating this disease effectively …

Background Magnetic nanoparticles (MNPs) have been widely used in medical diagnostic
research. In this work, two technologies, MNPs and polymerase chain reaction (PCR), were …

O monitoramento de doença residual mínima (DRM) em leucemia mielóide crônica é
extremamente importante, pois possibilita o diagnóstico precoce de eventuais recidivas da …

Advances in deconvoluting complex disease processes, enabling genomic, proteomic,
metabolomic and imaging technologies, highthroughput drug discovery and development …